Merck tailors emerging market strategies
By 2013, Merck & Co wants the leading emerging markets to account for a quarter of its revenues, representing a 50% hike from 2010. Dr Merv Turner, Merck's chief strategy officer, explains how the company, currently ranked fifth in emerging markets, plans to hit such an ambitious target.
Listen to Merv Turner in conversation with Scrip's Mike Ward |
Download the Merv Turner podcast in mp3 format Right click and select 'Save target/link as' from the menu |
Indian companies line up to emulate world champions
Anju Ghangurde, Scrip's India editor, outlines the growth strategies of some of India's leading domestic companies, alongside Western multinationals' diverse models for leveraging Indian pharma.
Click on the play button to listen to the podcast in Hindi
|
The voice of Australian pharma
Dr Brendan Shaw, Medicines Australia's chief executive, outlines the industry's position on the Federal Cabinet’s decision to block the listing of eight new products on the country's Pharmaceutical Benefits Scheme; plans to make Australian clinical trials more competitive; and a gene patents bill, introduced into parliament last year, which effectively disallows patents for biological medicines
